Hyponatremia induced by high-dose cyclophosphamide therapy: a retrospective cohort study Cyclophosphamide and Hyponatremia.
Cyclophosphamide-associated hyponatremia is an uncommon adverse effect. Published reports are inconclusive regarding patients under high-dose therapy. Objective: To determine the incidence of hyponatremia in patients under high-dose cyclophosphamide therapy. Methods: Retrospective cohort of adult pa...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Español |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2017
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/14766 |
| Aporte de: |
| id |
I10-R327-article-14766 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-327 |
| container_title_str |
Revista de la Facultad de Ciencias Médicas de Córdoba |
| language |
Español |
| format |
Artículo revista |
| topic |
hiponatremia ciclofosfamida movilización stem cells hematopoyéticas efecto adverso drogas hyponatremia cyclophosphamide hematopoietic stem cell mobilization drug side effects. |
| spellingShingle |
hiponatremia ciclofosfamida movilización stem cells hematopoyéticas efecto adverso drogas hyponatremia cyclophosphamide hematopoietic stem cell mobilization drug side effects. Bonella, Belen Maria Warley, Fernando Hyponatremia induced by high-dose cyclophosphamide therapy: a retrospective cohort study Cyclophosphamide and Hyponatremia. |
| topic_facet |
hiponatremia ciclofosfamida movilización stem cells hematopoyéticas efecto adverso drogas hyponatremia cyclophosphamide hematopoietic stem cell mobilization drug side effects. |
| author |
Bonella, Belen Maria Warley, Fernando |
| author_facet |
Bonella, Belen Maria Warley, Fernando |
| author_sort |
Bonella, Belen Maria |
| title |
Hyponatremia induced by high-dose cyclophosphamide therapy: a retrospective cohort study Cyclophosphamide and Hyponatremia. |
| title_short |
Hyponatremia induced by high-dose cyclophosphamide therapy: a retrospective cohort study Cyclophosphamide and Hyponatremia. |
| title_full |
Hyponatremia induced by high-dose cyclophosphamide therapy: a retrospective cohort study Cyclophosphamide and Hyponatremia. |
| title_fullStr |
Hyponatremia induced by high-dose cyclophosphamide therapy: a retrospective cohort study Cyclophosphamide and Hyponatremia. |
| title_full_unstemmed |
Hyponatremia induced by high-dose cyclophosphamide therapy: a retrospective cohort study Cyclophosphamide and Hyponatremia. |
| title_sort |
hyponatremia induced by high-dose cyclophosphamide therapy: a retrospective cohort study cyclophosphamide and hyponatremia. |
| description |
Cyclophosphamide-associated hyponatremia is an uncommon adverse effect. Published reports are inconclusive regarding patients under high-dose therapy. Objective: To determine the incidence of hyponatremia in patients under high-dose cyclophosphamide therapy. Methods: Retrospective cohort of adult patients who received high-dose cyclophosphamide therapy between 2010 and 2014 at the Hospital Italiano de Buenos Aires. The primary end-point was hyponatremia (defined as plasma sodium levels < 135 mEq/L), and secondary end-points were symptomatic hyponatremia, severe hyponatremia (plasma sodium levels < 120 mEq/L). Results: A total of 96 patients received high-dose cyclophosphamide therapy during the study period. 27 patients met exclusion criteria and accounted for 28.1% , so that 69 patients were included in the primary analysis. Study population mean age was 56.5 years (SD 12.8) and 37.6% were female. The cumulative incidence were as follows: 52% (CI 95% 39¬–64) for hiponatremia, 5.8% (CI 95% 0–12) for severe hyponatremia, and 8.7% (CI 95% 1.3–16) for symptomatic hyponatremia. The only independent variable associated with the development of hyponatremia was female gender (OR 3.89, CI 95% 1.02–8.55, p=0.04). Cumulative incidence found in this study appears higher than in previous reports, probably because only patients under high-dose cyclophosphamide therapy were included. Cumulative incidence of severe and symptomatic hyponatremia were lower |
| publisher |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología |
| publishDate |
2017 |
| url |
https://revistas.unc.edu.ar/index.php/med/article/view/14766 |
| work_keys_str_mv |
AT bonellabelenmaria hyponatremiainducedbyhighdosecyclophosphamidetherapyaretrospectivecohortstudycyclophosphamideandhyponatremia AT warleyfernando hyponatremiainducedbyhighdosecyclophosphamidetherapyaretrospectivecohortstudycyclophosphamideandhyponatremia AT bonellabelenmaria hiponatremiainducidaporciclofosfamidaenaltasdosisestudiodecohorteretrospectiva AT warleyfernando hiponatremiainducidaporciclofosfamidaenaltasdosisestudiodecohorteretrospectiva |
| first_indexed |
2024-09-03T20:58:19Z |
| last_indexed |
2024-09-03T20:58:19Z |
| _version_ |
1809209989178327040 |
| spelling |
I10-R327-article-147662024-08-27T18:20:15Z Hyponatremia induced by high-dose cyclophosphamide therapy: a retrospective cohort study Cyclophosphamide and Hyponatremia. Hiponatremia inducida por Ciclofosfamida en altas dosis: estudio de cohorte retrospectiva Bonella, Belen Maria Warley, Fernando hiponatremia ciclofosfamida movilización stem cells hematopoyéticas efecto adverso drogas hyponatremia cyclophosphamide hematopoietic stem cell mobilization drug side effects. Cyclophosphamide-associated hyponatremia is an uncommon adverse effect. Published reports are inconclusive regarding patients under high-dose therapy. Objective: To determine the incidence of hyponatremia in patients under high-dose cyclophosphamide therapy. Methods: Retrospective cohort of adult patients who received high-dose cyclophosphamide therapy between 2010 and 2014 at the Hospital Italiano de Buenos Aires. The primary end-point was hyponatremia (defined as plasma sodium levels < 135 mEq/L), and secondary end-points were symptomatic hyponatremia, severe hyponatremia (plasma sodium levels < 120 mEq/L). Results: A total of 96 patients received high-dose cyclophosphamide therapy during the study period. 27 patients met exclusion criteria and accounted for 28.1% , so that 69 patients were included in the primary analysis. Study population mean age was 56.5 years (SD 12.8) and 37.6% were female. The cumulative incidence were as follows: 52% (CI 95% 39¬–64) for hiponatremia, 5.8% (CI 95% 0–12) for severe hyponatremia, and 8.7% (CI 95% 1.3–16) for symptomatic hyponatremia. The only independent variable associated with the development of hyponatremia was female gender (OR 3.89, CI 95% 1.02–8.55, p=0.04). Cumulative incidence found in this study appears higher than in previous reports, probably because only patients under high-dose cyclophosphamide therapy were included. Cumulative incidence of severe and symptomatic hyponatremia were lower Antecedentes: La hiponatremia asociada al uso de Ciclofosfamida es un efecto adverso infrecuente. Los estudios publicados no son concluyentes, especialmente respecto de los pacientes sometidos a dosis altas de dicho fármaco.Objetivos: Determinar la incidencia de hiponatremia en una subpoblación de pacientes que realizaron tratamiento con dosis altas de Ciclofosfamida.Materiales y Métodos: Estudio de cohorte retrospectivo de pacientes adultos que recibieron Ciclofosfamida a altas dosis en el período 2010-2014 en el Hospital Italiano de Buenos Aires. El evento primario fue la hiponatremia (definida como sodio plasmático menor a 135 meq/L) mientras que como eventos secundarios se tomaron la hiponatremia sintomática y la hiponatremia severa (valor menor 120 meq/L).Resultados: 96 pacientes recibieron altas dosis de Ciclofosfamida durante el período estudiado. Se excluyó un 27.4% de los pacientes por cumplir con los criterios de exclusión y se analizaron los datos de 69 pacientes. La edad media de la población fue de 56.5 años (DS 12.8) y un 37.7% de los pacientes eran mujeres. La incidencia de hiponatremia fue de 52% (IC95% 39-64), hiponatremia severa 5.8% (IC95% 0-12) y sintomática 8.7% (IC95% 1.3-16). La única variable asociada independientemente al desarrollo de hiponatremia fue el sexo femenino (OR: 3.89, IC95% 1.02-8.55, p=0.04). Si bien la incidencia observada resulta mayor a la observada en reportes previos, probablemente se deba a que solo consideramos la infusión de Ciclofosfamida a altas dosis. La hiponatremia severa y sintomática fue menor, aunque un 20% de los pacientes debieron prolongar su internación por esta causa. Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2017-09-08 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion application/pdf application/msword application/msword https://revistas.unc.edu.ar/index.php/med/article/view/14766 10.31053/1853.0605.v74.n3.14766 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 74 No. 3 (2017); 201-206 Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 74 Núm. 3 (2017); 201-206 Revista da Faculdade de Ciências Médicas de Córdoba; v. 74 n. 3 (2017); 201-206 1853-0605 0014-6722 10.31053/1853.0605.v74.n3 spa https://revistas.unc.edu.ar/index.php/med/article/view/14766/18480 https://revistas.unc.edu.ar/index.php/med/article/view/14766/26090 https://revistas.unc.edu.ar/index.php/med/article/view/14766/26091 Derechos de autor 2017 Universidad Nacional de Córdoba https://creativecommons.org/licenses/by-nc/4.0 |